School of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Yunnan, Kunming 650500, China.
Department of Pharmacy, Panzhihua Central Hospital, Sichuan, Panzhihua 617067, China.
J Immunol Res. 2022 Apr 20;2022:3851604. doi: 10.1155/2022/3851604. eCollection 2022.
Malignant tumors have become the main cause of harm to human life and health. Development for new antitumor drugs and the exploration to drug carriers are becoming the concerned focus. In this study, we exploited our experiments to explore the effect of NCTD-NLC on liver cancer cells: the HepG2 cells cultured in vitro were given with NCTD-NLC administration; then, the estimation on cellular proliferation and apoptosis was accomplished through MTT and flow cytometry. Six hours after the administration, we performed the High Performance Liquid Chromatography (HPLC) detection to estimate the NCTD content in the heart, liver, spleen, lung, kidney and plasma of rats. Then, our outcomes showed that NCTD-NLC had a notable inhibitory effect on HepG2 cells, leading to a gradually decreased cellular viability. Cell viability was negatively correlated with NCTD-NLC concentration. Along with the concentration increasing, significantly increasing cellular apoptosis and gradually decreasing cellular viability were observed. The apoptosis rate was positively correlated with the concentration of NCTD-NLC. On the basis of the data we obtained, we found that the group with NCTD-NLC tail vein injection had an obvious advantage in drug delivery when compared with other groups. Through the tumorigenesis test to nude mice, we found that the tumor inhibition rate of the NCTD-NLC tail vein injection group had a 27.48% elevation in contrast to the NCTD gavage group, and it was also the group with the best tumor inhibition efficiency. In conclusion, the NCTD-NLC prepared in this study had a mighty inhibitory effect towards HepG2 cellular viability and an accelerating work on apoptosis. Tail vein injection of NCTD-NLC has the best drug delivery effect.
恶性肿瘤已成为危害人类生命和健康的主要原因。开发新的抗肿瘤药物和探索药物载体已成为关注的焦点。在这项研究中，我们通过实验来探索 NCTD-NLC 对肝癌细胞的影响：将体外培养的 HepG2 细胞给予 NCTD-NLC 给药；然后，通过 MTT 和流式细胞术评估细胞增殖和凋亡。给药 6 小时后，我们进行高效液相色谱（HPLC）检测以评估大鼠心脏、肝脏、脾脏、肺、肾脏和血浆中的 NCTD 含量。结果表明，NCTD-NLC 对 HepG2 细胞具有明显的抑制作用，导致细胞活力逐渐降低。细胞活力与 NCTD-NLC 浓度呈负相关。随着浓度的增加，观察到细胞凋亡显著增加，细胞活力逐渐降低。细胞凋亡率与 NCTD-NLC 浓度呈正相关。根据我们获得的数据，我们发现与其他组相比，NCTD-NLC 尾静脉注射组在药物递送方面具有明显优势。通过裸鼠肿瘤发生试验，我们发现与 NCTD 灌胃组相比，NCTD-NLC 尾静脉注射组的肿瘤抑制率提高了 27.48%，是肿瘤抑制效率最高的组。总之，本研究制备的 NCTD-NLC 对 HepG2 细胞活力具有强大的抑制作用，并加速细胞凋亡。NCTD-NLC 尾静脉注射具有最佳的药物递送效果。
